Compare CRSP & FULT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | FULT |
|---|---|---|
| Founded | 2013 | 1882 |
| Country | Switzerland | United States |
| Employees | 393 | 3400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | FULT |
|---|---|---|
| Price | $51.20 | $24.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | ★ $70.29 | $21.75 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $6.39 |
| Revenue Next Year | $172.52 | $5.52 |
| P/E Ratio | ★ N/A | $10.58 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $16.60 |
| 52 Week High | $78.48 | $24.71 |
| Indicator | CRSP | FULT |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 65.15 |
| Support Level | $47.92 | $23.51 |
| Resistance Level | $59.61 | $24.71 |
| Average True Range (ATR) | 3.39 | 0.45 |
| MACD | -0.83 | -0.05 |
| Stochastic Oscillator | 12.78 | 82.92 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.